Diabetes prevalence and risk factors in polycystic ovary syndrome

Current Opinion in Endocrinology and Diabetes

Volumn 9, Issue 6, 2002, Pages 451-458

  Legro, Richard S ^a,b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; GLUCOSE; INSULIN; METFORMIN;

ANDROGEN RELEASE; ANOVULATION; CHRONIC DISEASE; CORRELATION ANALYSIS; DIET RESTRICTION; ETHNOLOGY; FAMILY HISTORY; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HIGH RISK POPULATION; HORMONE ACTION; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN RESISTANCE; MENSTRUAL IRREGULARITY; MINORITY GROUP; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PANCREAS ISLET BETA CELL; PHENOTYPE; PREGNANCY; PREGNANCY DIABETES MELLITUS; PRELIMINARY COMMUNICATION; PREVALENCE; PROSPECTIVE STUDY; REPRODUCTION; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; RURAL POPULATION; SCREENING; UNITED STATES; URBAN POPULATION;

EID: 0038010509     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200212000-00003     Document Type: Review

References (62)

1. Knowler WC, Barrett-Connor E, Fowler SE, et al., and the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403. This study, which documents the prevention of diabetes in a high risk population (glucose intolerance) with either lifestyle interventions or metformin therapy highlight the clinical importance of detecting glucose intolerance in women with PCOS.
2. Legro RS, Kunselman AR, Dodson WC, et al.: Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999, 84:165-169.
3. Ehrmann DA, Barnes RB, Rosenfield RL, et al.: Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999, 22:141-146.
4. Sinha R, Fisch G, Teague B, et al.: Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002 Mar 14, 346:802-810.
5. Palmert MR, Gordon CM, Kartashov A, et al.: Screening for Abnormal Glucose Tolerance in Adolescents with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2002, 87:1017-1023. This study demonstrated a high prevalence of glucose intolerance (27%) of adolescent females with PCOS and showed that traditional fasting measures are a poor screening test to detect glucose intolerance.
6. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997, 18:774-800.
7. Dunaif A, Segal KR, Futterweit W, et al.: Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989, 38:1165-1174.
8. Pimenta W, Korytkowski M, Mitrakou A, et al.: Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA 1995, 273:1855-1861.
9. O'Meara NM, Blackman JD, Ehrmann DA, et al.: Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993, 76:1241-1247.
10. Dunaif A, Finegood DT. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996, 81:942-947.
11. Dunaif A, Graf M, Mandeli J, et al.: Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987, 65:499-507.
12. Harris MI, Hadden WC, Knowler WC, et al.: Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 years. Diabetes 1987, 36:523-534.
13. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al.: Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998, 83:3078-3082.
14. Falsetti L, Eleftheriou G. Hyperinsulinemia in the polycystic ovary syndrome-a clinical, endocrine, and echographic study in 240 patients. Gynecol Endocrinol 1996, 10:319-326.
15. Lewy VD, Danadian K, Witchel SF, et al.: Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr 2001, 138:38-44. Adolescents with PCOS and impaired glucose tolerance were studied with the hyperglycemic clamp for insight into the pathogenesis of this disorder. The failure of the beta cell to compensate for the degree of peripheral resistance is well documented in this study.
16. Arslanian SA. Type 2 diabetes mellitus in children: pathophysiology and risk factors. J Ped Endocrinol Metab 2000, 13 Suppl 6:1385-1394.
17. Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab 2001,86:66-71. The roles of insulin resistance and insulin secretion in the pathogenesis of glucose intolerance in polycystic ovary syndrome (PCOS) were evaluated in obese adolescents with glucose intolerance. Multiple metabolic abnormalities of insulin action were noted and an absence of nocturnal dipping in blood pressure, which are precursors of type 2 diabetes and present earlier in the course of PCOS then previously suspected.
18. Ehrmann DA, Barnes RB, Rosenfield RL, et al.: Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999, 22:141-146.
19. Solomon CG, Rich-Edwards JW, Dunaif A, et al.: Abnormal menstrual cycle length predicts subsequent diabetes mellitus. Am J Epidemiol 1998, 11 (Suppl):S237.
20. Moghetti P, Castello R, Negri C, et al.: Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000, 85:139-146.
21. Azziz R, Ehrmann D, Legro RS, et al., and the PCOS/Troglitazone Study Group. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001 Apr, 86:1626-1632.
22. Barbieri RL. Hyperandrogenism, insulin resistance and Acanthosis nigricans. 10 years of progress. J Reprod Med 1994, 39:327-336.
23. Legro RS, Bentley-Lewis R, Driscoll D, et al.: Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. J Clin Endocrinol Metab 2002, 87:2128-2133. This article provides evidence that hyperandrogenemia per se, at least in PCOS families may be an independent risk factor for hyperinsulinemia and other metabolic abnormalities.
24. Franks S. Polycystic ovary syndrome N Engl J Med 1995, 333:853-861.
25. Legro RS, Spielman R, Urbanek M, et al.: Phenotype and genotype in polycystic ovary syndrome. Recent Prog Horm Res 1998, 53:217-256.
26. Farquhar CM, Birdsall M, Manning P, et al.: The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. Aust N Z J Obstet Gynaecol 1994, 34:67-72.
27. Polson DW, Adams J, Wadsworth J, et al.: Polycystic ovaries-a common finding in normal women. Lancet 1988, 1:870-872.
28. Carmina E, Wong L, Chang L, et al.: Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound. Hum Reprod 1997, 12:905-909.
29. Chang PL, Lindheim SR, Lowre C, et al.: Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing. J Clin Endocrinol Metab 2000, 85:995-1000.
30. Conn JJ, Jacobs HS, Conway GS. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2000 Jan, 52:81-86.
31. Colditz GA, Willett WC, Stampfer MJ, et al.: Weight as a risk factor for clinical diabetes in women. Am J Epidemiol 1990, 132:501-513.
32. Robinson S, Kiddy D, Gelding SV, et al.: The relation of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin Endocrinol 1993, 39:351-355.
33. Wild RA. Obesity, lipids, cardiovascular risk, and androgen excess. Am J Med 1995, 98:27S-32S.
34. Alford FP, Henriksen JE, Rantzau C, et al.: Impact of family history of diabetes on the assessment of beta-cell function. Metabolism Clin Exp 1998 May, 47:522-528.
35. Fernandez-Castaner M, Biarnes J, Camps I, et al.: Beta-cell dysfunction in first-degree relatives of patients with non-insulin-dependent diabetes mellitus. Diabet Med 1996, 13:953-959.
36. Stewart MW, Humphriss DB, Berrish TS, et al.: Features of syndrome X in first-degree relatives of NIDDM patients. Diabetes Care 1995, 18:1020-1022.
37. Ehrmann DA, Sturis J, Byrne MM, et al.: Insulin secretory defects in polycystic ovary syndrome. Relation to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 1995, 96:520-527.
38. Saad MF, Knowler WC, Pettitt DJ, et al.: A two-step model for development of non-insulin-dependent diabetes. Am J Med 1991, 90:229-235.
39. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14:173-194.
40. Kjos SL, Buchanan TA. Gestational diabetes mellitus. N Engl J Med 1999, 341:1749-1756.
41. Kjos SL, Peters RK, Xiang A, et al.: Predicting future diabetes in Latino women with gestational diabetes. Utility of early postpartum glucose tolerance testing. Diabetes 1995, 44:586-591.
42. Kousta E, Cela E, Lawrence N, et al.: The prevalence of polycystic ovaries in women with a history of gestational diabetes. Clin Endocrinol (Oxf) 2000 Oct, 53:501-507.
43. Anttila L, Karjala K, Penttila RA, et al.: Polycystic ovaries in women with gestational diabetes. Obstet Gynecol 1998, 92:13-16.
44. Koivunen RM, Juutinen J, Vauhkonen I, et al.: Metabolic and steroidogenic alterations related to increased frequency of polycystic ovaries in women with a history of gestational diabetes. J Clin Endocrinol Metab 2001, 86:2591-2599. This is an excellent follow-up study of women with gestational diabetes after delivery which identifies that Compared with control women, women with previous gestational diabetes more often had significantly abnormal glucose tolerance and a higher prevalence of polycystic ovaries.
45. Harris MI. Gestational diabetes may represent discovery of preexisting glucose intolerance. Diabetes Care 1988, 11:402-411.
46. Lanzone A, Caruso A, Di Simone N, et al.: Polycystic ovary disease. A risk factor for gestational diabetes? J Reprod Med 1995, 40:312-316.
47. Vollenhoven B, Clark S, Kovacs G, et al.: Prevalence of gestational diabetes mellitus in polycystic ovarian syndrome (PCOS) patients pregnant after ovulation induction with gonadotrophins. Aust N Z J Obstet Gynaecol 2000, 40:54-58.
48. Carmina E, Koyama T, Chang L, et al.: Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol 1992, 167:1807-1812.
49. Norman RJ, Mahabeer S, Masters S. Ethnic differences in insulin and glucose response to glucose between white and Indian women with polycystic ovary syndrome. Fertil Steril 1995, 63:58-62.
50. Dunaif A, Sorbara L, Delson R, et al.: Ethnicity and polycystic ovary syndrome are associated with independent and additive decreases in insulin action in Caribbean-Hispanic women. Diabetes 1993, 42:1462-1468.
51. Osei K, Schuster DP. Ethnic differences in secretion, sensitivity, and hepatic extraction of insulin in black and white Americans. Diabet Med 1994, 11:755-762.
52. Palaniappan LP, Carnethon MR, Fortmann SP. Heterogeneity in the relation between ethnicity, BMI, and fasting insulin. Diabetes Care 2002 25:1351-1357.
53. Golland IM, Vaughan Williams CA, Shalet SM, et al.: Lack of predictive value of HbA1c for impaired glucose tolerance in polycystic ovary syndrome. Gynecol Endocrinol 1989, 3:229-235.
54. Harris MI, Eastman RC, Cowie CC, et al.: Comparison of diabetes diagnostic categories in the U.S. population according to 1997 American Diabetes Association and 1980-1985 World Health Organization diagnostic criteria. Diabetes Care 1997, 20:1859-1862.
55. Harris MI. Impaired glucose tolerance-prevalence and conversion to NIDDM. Diabet Med 1996, 13:S9-11.
56. Ferrannini E, Vichi S, Beck-Nielsen H, et al.: Insulin action and age. European Group for the Study of Insulin Resistance (EGIR). Diabetes 1996, 45:947-953.
57. Saad MF, Knowler WC, Pettitt DJ, et al.: The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med 1988, 319:1500-1506.
58. Dahlgren E, Johansson S, Lindstedt G, et al.: Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 1992, 57:505-513.
59. Talbott E, Clerici A, Berga SL, et al.: Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 1998, 51:415-422.
60. Elting MW, Korsen TJ, Bezemer PD, et al.: Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod 2001, 16:556-560. This was an important follow-up study in a thin Dutch PCOS population investigating the prevalence of diabetes mellitus, hypertension, and cardiac complaints in a Dutch population with polycystic ovarian syndrome (PCOS) compared with theprevalence of these conditions in the Dutch female population. A slight but increased risk was identified in women with PCOS in their 40's.
61. Wild S, Pierpoint T, McKeigue P, et al.: Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000 May, 52:595-600.
62. Norman RJ, Masters L, Milner CR, et al.: Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001, 16:1995-1998. This is the largest study to date of the conversion rates to impaired glucose tolerance or to type 2 diabetes in a cohort of 67 women with PCOS. 17% of the women with normal glucose tolerance progressed and 54% of the women with IGT progressed.